Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Hisse Senetlerindeki Sıralama #174
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity,... Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Hisse Fiyatı
$62.26
Son senkronizasyon: 2026-09-22
Piyasa Değeri
$127.18B
Değişim (1 gün)
-0.78%
Değişim (1 yıl)
38.63%
Ülke
US
Ticaret Bristol-Myers Squibb Company (BMY)

Kategori

Bristol-Myers Squibb Company (BMY) için Faaliyet Marjı
September 2026 itibarıyla Faaliyet Marjı TTM: 28.27%
Bristol-Myers Squibb Company şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) 28.27%'dir. 2024 yılı sonunda şirketin faaliyet marjı 20.00% idi.
Bristol-Myers Squibb Company için 2000 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
Yıl Faaliyet Marjı Değiştir
2026 (TTM) 28.27% 7.33%
2025 26.34% 31.70%
2024 20.00% 6.27%
2023 18.82% -6.27%
2022 20.08% -2.38%
2021 20.57% 94.79%
2020 10.56% -57.13%
2019 24.63% -13.09%
2018 28.34% 12.37%
2017 25.22% -5.40%
2016 26.66% 12.11%
2015 23.78% 20.47%
2014 19.74% 3.35%
2013 19.10% -21.14%
2012 24.22% -23.79%
2011 31.78% 0.92%
2010 31.49% 17.32%
2009 26.84% 13.39%
2008 23.67% 21.57%
2007 19.47% 32.00%
2006 14.75% -31.33%
2005 21.48% -11.42%
2004 24.25% 2.71%
2003 23.61% 4.33%
2002 22.63% -14.80%
2001 26.56% -19.17%
2000 32.86% 0.00%
Benzer şirketler veya rakipler için Faaliyet Marjı
Şirket Faaliyet Marjı Faaliyet Marjı Farkı Ülke
43.92% -98.45%
US
26.81% -99.05%
US
29.32% -98.96%
US
26.59% -99.06%
CH
16.65% -99.41%
US
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.